Connect Biopharma (CNTB) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Connect Biopharma (NASDAQ: CNTB) recently:

• 7/9/2026 – Connect Biopharma is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $8.00 price target on the stock.
• 6/30/2026 – Connect Biopharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 6/28/2026 – Connect Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 6/26/2026 – Connect Biopharma is now covered by Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 6/25/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 6/20/2026 – Connect Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/18/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.

Insider Transactions at Connect Biopharma

In other news, Director James Huang acquired 150,000 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were purchased at an average cost of $2.48 per share, with a total value of $372,000.00. Following the acquisition, the director directly owned 13,310,000 shares in the company, valued at $33,008,800. This represents a 1.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 22.60% of the stock is owned by company insiders.

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.